鼻内催产素预防急诊患者创伤后应激障碍症状:一项随机对照试验
这项多中心随机双盲安慰剂对照试验纳入120名急诊成年患者(85%为事故受害者),在创伤后12天内启动鼻内催产素(8天/40 IU每日两次)或安慰剂。意向治疗分析107人,结果显示创伤后1.5个月CAPS总分无显著组间差异,但基线CAPS高分者接受催产素后随访期间CAPS评分显著低于安慰剂组。
要点
- 创伤后早期鼻内催产素未能减轻全部急性痛苦患者的临床医生评定PTSD症状。
- 基线急性PTSD症状严重者接受催产素后随访CAPS评分显著低于安慰剂组。
- 结果需重复验证,催产素可能对高急性PTSD症状个体有预防前景。
核心结论
- 创伤后早期鼻内催产素未在所有急性痛苦创伤暴露者中减轻临床医生评定的PTSD症状。
- 基线临床医生评定PTSD症状严重度高的参与者接受催产素后显示出有益效果。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验。
- 纳入120名急诊成年患者,中重度急性痛苦,85%为事故受害者。
- 鼻内催产素8天/40 IU每日两次或安慰剂8天/10喷每日两次,创伤后12天内启动。
- 意向治疗样本107人(催产素53人,安慰剂54人)。
主要发现
- 创伤后1.5个月CAPS总分(主要结局)无显著组间差异。
- 随访期间CAPS总分(次要结局)无显著组间差异。
- 基线CAPS高分者中,催产素组随访期间CAPS评分显著低于安慰剂组。
关键数值与推荐
- 主要结局为创伤后1.5个月CAPS总分,未报告显著组间差异。
- 次要结局为随访期间CAPS总分,未报告显著组间差异。
- 基线CAPS高分者接受催产素后随访CAPS评分显著低于安慰剂组。
临床怎么用
- 目前证据不支持对所有急诊急性痛苦创伤暴露者常规使用鼻内催产素预防PTSD。
- 对基线急性PTSD症状严重者,鼻内催产素可能是有前景的预防干预,但需重复验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are currently few preventive interventions available for posttraumatic stress disorder (PTSD). Intranasal oxytocin administration early after trauma may prevent PTSD, because oxytocin administration was previously found to beneficially impact PTSD vulnerability factors, including neural fear responsiveness, peripheral stress reactivity, and socioemotional functioning. Therefore, we investigated the effects of intranasal oxytocin administration early after trauma on subsequent clinician-rated PTSD symptoms. We then assessed whether baseline characteristics moderated the intervention's effects. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled clinical trial. Adult emergency department patients with moderate to severe acute distress (n = 120; 85% accident victims) were randomized to intranasal oxytocin (8 days/40 IU twice daily) or placebo (8 days/10 puffs twice daily), initiated within 12 days posttrauma. The Clinician-Administered PTSD Scale (CAPS) was administered at baseline (within 10 days posttrauma) and at 1.5, 3, and 6 months posttrauma. The intention-to-treat sample included 107 participants (oxytocin: n = 53; placebo: n = 54). RESULTS: We did not observe a significant group difference in CAPS total score at 1.5 months posttrauma (primary outcome) or across follow-up (secondary outcome). Secondary analyses showed that participants with high baseline CAPS scores receiving oxytocin had significantly lower CAPS scores across follow-up than participants with high baseline CAPS scores receiving placebo. CONCLUSIONS: Oxytocin administration early after trauma did not attenuate clinician-rated PTSD symptoms in all trauma-exposed participants with acute distress. However, participants with high acute clinician-rated PTSD symptom severity did show beneficial effects of oxytocin. Although replication is warranted, these findings suggest that oxytocin administration is a promising preventive intervention for PTSD for individuals with high acute PTSD symptoms.
引用
- van Zuiden M, Frijling JL, Nawijn L, et al. Intranasal Oxytocin to Prevent Posttraumatic Stress Disorder Symptoms: A Randomized Controlled Trial in Emergency Department Patients. Biol Psychiatry. 2016. PMID: 28087128. doi:10.1016/j.biopsych.2016.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。